

Tyler Adam

Discloser Identifier: 1108104

Disclosure Purpose: 22-16480

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer Inc.	Other	Self
<i>Category:</i> Other <i>Description:</i> Pfizer research principle investigator <i>Additional Information:</i>		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Bivalent RSVpreF Vaccine in Pregnancy to Prevent RSV Illness in Infants

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Annaliesa Anderson

Discloser Identifier: 737710

Disclosure Purpose: 22-16480

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer Inc.	Employment	Self
<i>Title:</i> Senior Vice President and Chief Scientific Officer Vaccines Research and Development <i>Position Description:</i> <i>Additional Information:</i>		
Pfizer Inc.	Stock	Self
<i>Additional Information:</i>		
Pfizer Inc.	Stock Option	Self
<i>Additional Information:</i>		

Intellectual Property

Type	Is Licensed	Interest Held By
Patent - Escherichia Coli Compositions and Methods Thereof	-	Self
<i>Description:</i> Escherichia Coli Compositions and Methods Thereof <i>Patent Status:</i> <i>Filing Jurisdiction:</i> <i>Licensees:</i> <i>Additional Information:</i> <i>Patent Number:</i> PCT/IB2019/057025 <i>Patent Holder:</i>		
Patent - Compositions And Methods Of Use Of ORF1358 From B	-	Self
<i>Description:</i> Compositions And Methods Of Use Of ORF1358 From Beta-hemolytic Streptococcal Strains <i>Patent Status:</i> <i>Filing Jurisdiction:</i> <i>Licensees:</i> <i>Additional Information:</i> <i>Patent Number:</i> PCT/US2009/047902 <i>Patent Holder:</i>		
Patent - Group B Streptococcus Polysaccharide-protein Conj	-	Self
<i>Description:</i> Group B Streptococcus Polysaccharide-protein Conjugates, Methods for Producing Conjugates, Immunogen <i>Patent Status:</i> <i>Filing Jurisdiction:</i> <i>Licensees:</i> <i>Additional Information:</i> <i>Patent Number:</i> PCT/IB2021/057714 <i>Patent Holder:</i>		
Patent - Immunogenic Fusion Polypeptides	-	Self

Type	Is Licensed	Interest Held By
<i>Description:</i> Immunogenic Fusion Polypeptides <i>Patent Number:</i> PCT/IB2014/059462 <i>Patent Status:</i> <i>Patent Holder:</i> <i>Filing Jurisdiction:</i> <i>Licensees:</i> <i>Additional Information:</i>		
Patent - Non-Lipidated Variants of Neisseria Meningitidis	-	Self
<i>Description:</i> Non-Lipidated Variants of Neisseria Meningitidis ORF2086 Antigens <i>Patent Number:</i> PCT/IB2011/053934 <i>Patent Status:</i> <i>Patent Holder:</i> <i>Filing Jurisdiction:</i> <i>Licensees:</i> <i>Additional Information:</i>		
Patent - Vaccination Against Bacterial And Betacoronavirus	-	Self
<i>Description:</i> Vaccination Against Bacterial And Betacoronavirus Infections <i>Patent Number:</i> PCT/IB2022/053951 <i>Patent Status:</i> <i>Patent Holder:</i> <i>Filing Jurisdiction:</i> <i>Licensees:</i> <i>Additional Information:</i>		
Patent - Immunogenic Compositions Against Clostridioides (	-	Self
<i>Description:</i> Immunogenic Compositions Against Clostridioides (Clostridium) Difficile <i>Patent Number:</i> PCT/IB2021/055373 <i>And Methods Thereof</i> <i>Patent Holder:</i> <i>Patent Status:</i> <i>Filing Jurisdiction:</i> <i>Licensees:</i> <i>Additional Information:</i>		
Patent - Group B Streptococcus Polysaccharide-Protein Conj	-	Self
<i>Description:</i> Group B Streptococcus Polysaccharide-Protein Conjugates, Methods <i>Patent Number:</i> PCT/IB2016/052455 <i>For Producing Conjugates, Immunogen</i> <i>Patent Holder:</i> <i>Patent Status:</i> <i>Filing Jurisdiction:</i> <i>Licensees:</i> <i>Additional Information:</i>		
Patent - Compositions and Methods Relating to a Mutant Clo	-	Self
<i>Description:</i> Compositions and Methods Relating to a Mutant Clostridium Difficile <i>Patent Number:</i> PCT/IB2013/059183 <i>Toxin</i> <i>Patent Holder:</i> <i>Patent Status:</i> <i>Filing Jurisdiction:</i> <i>Licensees:</i> <i>Additional Information:</i>		
Patent - Neisseria Meningitidis Compositions And Methods T	-	Self
<i>Description:</i> Neisseria Meningitidis Compositions And Methods Thereof <i>Patent Number:</i> PCT/IB2018/050563 <i>Patent Status:</i> <i>Patent Holder:</i> <i>Filing Jurisdiction:</i> <i>Licensees:</i> <i>Additional Information:</i>		
Patent - Immunogenic compositions for use in pneumococcal	-	Self
<i>Description:</i> Immunogenic compositions for use in pneumococcal vaccines <i>Patent Number:</i> PCT/IB2021/060097 <i>Patent Status:</i> <i>Patent Holder:</i> <i>Filing Jurisdiction:</i> <i>Licensees:</i> <i>Additional Information:</i>		
Patent - Immunogenic Compositions Comprising Conjugated Ca	-	Self

Type	Is Licensed	Interest Held By
<i>Description:</i> Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens and Uses Thereof <i>Patent Status:</i> <i>Filing Jurisdiction:</i> <i>Licensees:</i> <i>Additional Information:</i> <i>Patent Number:</i> PCT/IB2022/054920 <i>Patent Holder:</i>		
Patent - Escherichia Coli Compositions And Methods Thereof	-	Self
<i>Description:</i> Escherichia Coli Compositions And Methods Thereof <i>Patent Status:</i> <i>Filing Jurisdiction:</i> <i>Licensees:</i> <i>Additional Information:</i> <i>Patent Number:</i> PCT/IB2020/060081 <i>Patent Holder:</i>		
Patent - Multicomponent Immunogenic Composition For The Pr	-	Self
<i>Description:</i> Multicomponent Immunogenic Composition For The Prevention Of Beta-hemolytic Streptococcal (BHS) Dise <i>Patent Status:</i> <i>Filing Jurisdiction:</i> <i>Licensees:</i> <i>Additional Information:</i> <i>Patent Number:</i> PCT/US2009/063268 <i>Patent Holder:</i>		
Patent - Neisseria Meningitidis Compositions And Methods T	-	Self
<i>Description:</i> Neisseria Meningitidis Compositions And Methods Thereof <i>Patent Status:</i> <i>Filing Jurisdiction:</i> <i>Licensees:</i> <i>Additional Information:</i> <i>Patent Number:</i> PCT/IB2014/064091 <i>Patent Holder:</i>		
Patent - Immunogenic Compositions Comprising Conjugated Ca	-	Self
<i>Description:</i> Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens, Kits Comprising the Sam <i>Patent Status:</i> <i>Filing Jurisdiction:</i> <i>Licensees:</i> <i>Additional Information:</i> <i>Patent Number:</i> PCT/IB2020/053280 <i>Patent Holder:</i>		
Patent - Neisseria Meningitidis Compositions and Methods T	-	Self
<i>Description:</i> Neisseria Meningitidis Compositions and Methods Thereof <i>Patent Status:</i> <i>Filing Jurisdiction:</i> <i>Licensees:</i> <i>Additional Information:</i> <i>Patent Number:</i> PCT/IB2013/051791 <i>Patent Holder:</i>		
Patent - Compositions And Methods Of Use Of ORF 554 From B	-	Self
<i>Description:</i> Compositions And Methods Of Use Of ORF 554 From Beta Hemolytic Streptococcal Strains <i>Patent Status:</i> <i>Filing Jurisdiction:</i> <i>Licensees:</i> <i>Additional Information:</i> <i>Patent Number:</i> PCT/US2009/047886 <i>Patent Holder:</i>		
Patent - Neisseria Meningitidis Compositions And Methods T	-	Self
<i>Description:</i> Neisseria Meningitidis Compositions And Methods Thereof <i>Patent Status:</i> <i>Filing Jurisdiction:</i> <i>Licensees:</i> <i>Additional Information:</i> <i>Patent Number:</i> PCT/IB2020/058928 <i>Patent Holder:</i>		
Patent - Compositions And Methods For Preparing Staphyloco	-	Self

Type	Is Licensed	Interest Held By
Description: Compositions And Methods For Preparing Staphylococcus Aureus Serotype 5 And 8 Capsular Polysaccharid Patent Status: Filing Jurisdiction: Licensees: Additional Information: Patent Number: PCT/US2010/039473 Patent Holder:		
Patent - Immunogenic Compositions Of Staphylococcus Aureus	-	Self
Description: Immunogenic Compositions Of Staphylococcus Aureus Antigens Patent Status: Filing Jurisdiction: Licensees: Additional Information: Patent Number: PCT/US2010/039510 Patent Holder:		
Patent - Compositions and Methods for Eliciting an Immune	-	Self
Description: Compositions and Methods for Eliciting an Immune Response Against Clostridium Difficile Patent Status: Filing Jurisdiction: Licensees: Additional Information: Patent Number: PCT/IB2020/053005 Patent Holder:		
Patent - Compositions Comprising Three OspA Fusion Protein	-	Self
Description: Compositions Comprising Three OspA Fusion Proteins For Medical Use Patent Status: Filing Jurisdiction: Licensees: Additional Information: Patent Number: PCT/US2021/026599 Patent Holder:		
Patent - Neisseria Meningitidis Compositions And Methods T	-	Self
Description: Neisseria Meningitidis Compositions And Methods Thereof Patent Status: Filing Jurisdiction: Licensees: Additional Information: Patent Number: PCT/IB2016/050829 Patent Holder:		
Patent - Compositions and Methods for Eliciting an Immune	-	Self
Description: Compositions and Methods for Eliciting an Immune Response Against Clostridium Difficile Patent Status: Filing Jurisdiction: Licensees: Additional Information: Patent Number: PCT/IB2018/057076 Patent Holder:		
Patent - Neisseria Meningitidis Compositions And Methods T	-	Self
Description: Neisseria Meningitidis Compositions And Methods Thereof Patent Status: Filing Jurisdiction: Licensees: Additional Information: Patent Number: PCT/IB2020/050988 Patent Holder:		
Patent - Escherichia Coli Compositions and Methods Thereof	-	Self
Description: Escherichia Coli Compositions and Methods Thereof Patent Status: Filing Jurisdiction: Licensees: Additional Information: Patent Number: PCT/IB2021/059820 Patent Holder:		
Patent - Immunogenic Compositions Comprising Conjugated Ca	-	Self

Type	Is Licensed	Interest Held By
Description: Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens And Uses Thereof Patent Status: Filing Jurisdiction: Licensees: Additional Information: Patent Number: PCT/IB2022/054914 Patent Holder:		
Patent - Compositions Relating To A Mutant Clostridium Dif	-	Self
Description: Compositions Relating To A Mutant Clostridium Difficile Toxin And Methods Thereof Patent Status: Filing Jurisdiction: Licensees: Additional Information: Patent Number: PCT/IB2012/051999 Patent Holder:		
Patent - Immunogenic Polysaccharide Protein Conjugated Com	-	Self
Description: Immunogenic Polysaccharide Protein Conjugated Comprising A Polysaccharide Derived From B Streptococc Patent Status: Filing Jurisdiction: Licensees: Additional Information: Patent Number: PCT/IB2017/056830 Patent Holder:		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Bivalent RSVpreF Vaccine in Pregnancy to Prevent RSV Illness in Infants

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

James Baber

Discloser Identifier: 995093

Disclosure Purpose: 22-16480

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer Australia	Employment	Self
<i>Title:</i> Senior Director, Vaccine Clinical Research and Development <i>Additional Information:</i>		
<i>Position Description:</i> Clinician		
Pfizer Inc.	Stock	Self
<i>Additional Information:</i>		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Bivalent RSVpreF Vaccine in Pregnancy to Prevent RSV Illness in Infants

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 1108086

Disclosure Purpose: 22-16480

Summary of Interests

Intellectual Property

Type	Is Licensed	Interest Held By
Other Intellectual Property - Principle Investigator for the study	-	Self
Description: Principle Investigator for the study Additional Information: Payment for work involved in screening, enrolling and managing all participants at my site involved in the study Type: paid for being a principle investigator in the study by Icon who was the CRO for Pfizer the sponsor of the study		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

Yes.

- a. **Please describe those relationships.**

I was a principle investigator for the study and paid to do that work

2. **What is the manuscript title?**

Bivalent RSVpreF Vaccine in Pregnancy to Prevent RSV Illness in Infants

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 1002219

Disclosure Purpose: 22-16480

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Prevention of RSV Illness with a Bivalent RSVpreF Vaccine in Pregnancy

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Louis Bont

Discloser Identifier: 331469

Disclosure Purpose: 22-16480

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AstraZeneca	Grant / Contract	Other - UMC Utrecht
<i>Recipient Name:</i> <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> <i>Grant / Contract Purpose:</i>
GlaxoSmithKline	Consultant	Other - UMC Utrecht
<i>Category:</i> Consultant <i>Description:</i> trial advise <i>Additional Information:</i>		
Janssen Pharmaceuticals	Grant / Contract	Other - UMC Utrecht
<i>Recipient Name:</i> <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> <i>Grant / Contract Purpose:</i>
Moderna	Data And Safety Monitoring	Other - UMC Utrecht
<i>Category:</i> Data And Safety Monitoring <i>Description:</i> RCT DSMB <i>Additional Information:</i> fees to UMCU		
Pfizer	Grant / Contract	Other - UMC Utrecht
<i>Recipient Name:</i> <i>Grant / Contract Description:</i> <i>Additional Information:</i>		<i>Recipient Type:</i> <i>Grant / Contract Purpose:</i>
Resvinet	Other	Other - UMC Utrecht
<i>Category:</i> Other <i>Description:</i> Founding Chairman <i>Additional Information:</i>		
SANOI PASTEUR INC.	Grant / Contract	Self
<i>Recipient Name:</i> UMC Utrecht <i>Grant / Contract Description:</i> RSV burden study <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Bivalent RSVpreF Vaccine in Pregnancy to Prevent RSV Illness in Infants

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

David Cooper

Discloser Identifier: 970668

Disclosure Purpose: 22-16480

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
Title: Executive Director Additional Information:		Position Description: Vaccine Researcher
Pfizer	Stock	Self
Additional Information:		
Pfizer	Stock Option	Self
Additional Information:		

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Bivalent RSVpreF Vaccine in Pregnancy to Prevent RSV Illness in Infants

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

MARIA DURON

Discloser Identifier: 1108119

Disclosure Purpose: 22-16480

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

"Bivalent RSVpreF Vaccine in Pregnancy to Prevent RSV Illness in Infants,"

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 1108096

Disclosure Purpose: 22-16480

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Instituto Científico Pfizer	Consultant	Self
Category: Consultant Description: I am the Principal Investigator for Boeson Research, LLC, contracted by Pfizer Additional Information: Boeson Research, LLC, an independent contracted company, participated in the multisite international RSV maternal vaccination clinical trials, phase II and phase III. Boeson compensates me as the PI for time spent supervising the trial in our local area. Duties include supervising research assistants, obtaining informed consent to participate, monitoring the health and safety of participants, and providing data on the outcomes of trial participants/subjects at our site/center.		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Prevention of RSV Illness with a Bivalent RSV preF Vaccine in Pregnancy.

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 1108090

Disclosure Purpose: 22-16480

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
Title: Director Additional Information: Position Description: Director, clinician monitor, vaccine clinical research and development		
Pfizer Inc.	Stock	Self
Additional Information:		

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Bivalent RSVpreF Vaccine in Pregnancy to Prevent RSV Illness in Infants

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

William Gruber

Discloser Identifier: 627453

Disclosure Purpose: 22-16480

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
Title: Senior Vice President Additional Information:		Position Description: Vaccine Clinical Research and Development Worldwide Research Development and Medical
Pfizer	Stock	Self
Additional Information:		
Pfizer	Stock Option	Self
Additional Information:		

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Bivalent RSVpreF Vaccine in Pregnancy to Prevent RSV Illness in Infants

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 777472

Disclosure Purpose: 22-16480

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Bivalent RSVpreF Vaccine in Pregnancy to Prevent RSV Illness in Infants

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Alejandra Gurtman

Discloser Identifier: 633953

Disclosure Purpose: 22-16480

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> VP Vaccine Clinical Research and Development <i>Additional Information:</i>		<i>Position Description:</i>

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Bivalent RSVpreF Vaccine in Pregnancy to Prevent RSV Illness in Infants

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 424802

Disclosure Purpose: 22-16480

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Bivalent RSVpreF Vaccine in Pregnancy to Prevent RSV Illness in Infants

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 627443

Disclosure Purpose: 22-16480

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer Inc.	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> vaccine consultant <i>Additional Information:</i> less than 10 hours a week		
Pfizer Inc.	Stock	Self
<i>Additional Information:</i> shareholder		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Bivalent RSVpreF vaccine to prevent RSV illness in infants

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Elena Kalinina

Discloser Identifier: 1108121

Disclosure Purpose: 22-16480

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer Inc.	Employment	Self
<i>Title:</i> Director <i>Additional Information:</i> <i>Position Description:</i> Cell culture operations		
Pfizer Inc.	Stock	Self
<i>Additional Information:</i>		
Pfizer Inc.	Stock Option	Self
Additional Information:		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Bivalent RSVpreF Vaccine in Pregnancy to Prevent RSV Illness in Infants

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Beate Kampmann

Discloser Identifier: 970881

Disclosure Purpose: 22-16480

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
PFIZER PHARMA GMBH	Grant / Contract	Self
<i>Recipient Name:</i> MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine <i>Grant / Contract Description:</i> Funding for Trial site <i>Additional Information:</i> Pfizer funded our research site to conduct the study as one of the participating sites- funding went to institution, not me <i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
PFIZER PHARMA GMBH	Travel	Self
<i>Location(s):</i> New York <i>Purpose:</i> Scientific Advisory Committee <i>Additional Information:</i> I participated in protocol development as part of external advisory board		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Bivalent RSVpreF Vaccine in Pregnancy to Prevent RSV Illness in Infants

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Anu Kantele

Discloser Identifier: 920672

Disclosure Purpose: 22-16480

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Instituto Científico Pfizer	Grant / Contract	Self
<i>Recipient Name:</i> HUCH Institute <i>Grant / Contract Description:</i> Investigator-initiated grant (hepA + Pnc vaccine study). No personal funding. <i>Additional Information:</i> No personal funding. <i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
Meilahti Vaccine Research Center MeVac	Employment	Self
<i>Title:</i> Head of Meilahti Vaccine Research Center MeVac <i>Position Description:</i> MeVac serves as one of many international centers in conducting international multi center studies of various vaccine companies. In addition, MeVac conducts academic investigator-initiated studies. The head of MeVac leads the center and its projects. <i>Additional Information:</i> As head of MeVac Vaccine Research Center contacts with all vaccine companies whose studies are conducted at MeVac. The companies cover the costs of the studies to the institute. No personal funding or payments received from the companies.		
Valneva Austria GmbH	Grant / Contract	Self
<i>Recipient Name:</i> Anu Kantele <i>Grant / Contract Description:</i> Investigator-initiated grant to a cholera+typhoid vaccine study. Funding to the institute. <i>Additional Information:</i> Grant to cover study costs paid to the institute. No personal funding or payments. <i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Bivalent RSVpreF Vaccine in Pregnancy to Prevent RSV Illness in Infants

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Kenneth Koury

Discloser Identifier: 970666

Disclosure Purpose: 22-16480

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Executive Director <i>Additional Information:</i>		<i>Position Description:</i> Head of Statistics and Modeling, Vaccine Clinical Research and Development
Pfizer	Stock	Self
<i>Additional Information:</i>		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Bivalent RSVpreF Vaccine in Pregnancy to Prevent RSV Illness in Infants

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Conrado Llapur

Discloser Identifier: 857692

Disclosure Purpose: 22-16480

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Bivalent RSVpreF Vaccine in Pregnancy to Prevent RSV Illness in Infants

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 884468

Disclosure Purpose: 22-16480

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer Inc.	Grant / Contract	Other - Funding to institution
<i>Recipient Name:</i> Wits Health Consortium <i>Grant / Contract Description:</i> Funding for study being undertaken for RSV vaccine developed by Pfizer <i>Additional Information:</i> All funds to institution for conduct of the study <i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Bivalent RSVpreF Vaccine in Pregnancy to Prevent RSV Illness in Infants

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 995102

Disclosure Purpose: 22-16480

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Senior Director <i>Additional Information:</i> full time <i>Position Description:</i> Vaccine Clinical Research and Development		
Pfizer	Stock	Self
<i>Additional Information:</i>		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Bivalent RSVpreF Vaccine in Pregnancy to Prevent RSV Illness in Infants

3. **Are you the corresponding author?**

Yes.

- a. **Please list the other authors' names here.**

Kampmann B, Madhi S, Munjal I, Simoes E, Pahud B, Llapur C, Baker J, Perez Marc G, Radley D, Shittu E, Glanternik J, Snaggs H, Baber J, Zachariah P, Barnabas S, Fausett M, Adam T, Perreras N, Van Houten M, Kantele A, Huang L-M, Bont L, Otsuki T, Vargas S, Gullam J, Tapiero B, Stein R, Polack F, Zar H, Staerke N, Duron Padilla M, Richmond P, Koury K, Schneider K, Kalinina E, Cooper D, Jansen K., Anderson A, Swanson K, Gruber W, Gurtman A, On behalf of the MATISSE study group

Certification

I certify that the information provided in this disclosure is complete and accurate.

Takeo Otsuki

Discloser Identifier: 1108109

Disclosure Purpose: 22-16480

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Bivalent RSVpreF Vaccine in Pregnancy to Prevent RSV Illness in Infants

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Barbara Pahud

Discloser Identifier: 1049035

Disclosure Purpose: 22-16480

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
Title: Director Additional Information: Position Description: Clinical Lead		
Pfizer	Stock	Self
Additional Information:		
Pfizer	Stock Option	Self
Additional Information:		

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Bivalent RSVpreF Vaccine in Pregnancy to Prevent RSV Illness in Infants

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Maria Angela Nicole Perreras

Discloser Identifier: 1108105

Disclosure Purpose: 22-16480

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Bivalent RSVpreF Vaccine in Pregnancy to Prevent RSV Illness in Infants

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Fernando Polack

Discloser Identifier: 1100402

Disclosure Purpose: 22-16480

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
iTrials SA	Stock	Self
<i>Additional Information:</i> scientific site management organization		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Bivalent RSVpreF Vaccine in Pregnancy to Prevent RSV Illness in Infants

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 1100401

Disclosure Purpose: 22-16480

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Medicago	Other	Self
<i>Category:</i> Other <i>Description:</i> Clinical Trial <i>Additional Information:</i> SARS COV-2 vaccine against COVID-19. Principal Investigator. I have signed a FDA Form 1572 or an Investigator Agreement. I receive funds.		
Merck	Other	Self
<i>Category:</i> Other <i>Description:</i> Clinical Trial <i>Additional Information:</i> Anti-RSV Antibody in Newborns. Sub-Investigator. I have signed a FDA Form 1572 or an Investigator Agreement. I have received funds.		
Moderna	Other	Self
<i>Category:</i> Other <i>Description:</i> Clinical Research; Speaker <i>Additional Information:</i>		
Pfizer	Other	Self
<i>Category:</i> Other <i>Description:</i> Clinical Trials <i>Additional Information:</i> 1. Anti-RSV vaccine in pregnant women. Principal Investigator (2021-?) 2. Pediatric Antireflux treatment. Principal Investigator. (2019-?) 3. SARS COV-2 RNA vaccine against COVID19. Sub-Investigator. (2021-?) - In every study I have signed a FDA Form 1572 or an Investigator Agreement. - In every study I have received funds and compensation to attend to an investigator meeting.		

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Bivalent RSVpreF Vaccine in Pregnancy to Prevent RSV Illness in Infants

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



David Radley

Discloser Identifier: 737716

Disclosure Purpose: 22-16480

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer Inc.	Employment	Self
Title: Executive Director Additional Information: Position Description: Lead Statistician		
Pfizer Inc.	Stock	Self
Additional Information:		
Pfizer Inc.	Stock Option	Self
Additional Information:		

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Bivalent RSVpreF Vaccine in Pregnancy to Prevent RSV Illness in Infants

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Peter Richmond

Discloser Identifier: 836932

Disclosure Purpose: 22-16480

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AstraZeneca Australia	Other	Other - University of Western Australia
Category: Other Description: Speaker Engagement Additional Information: Invited virtual speaker on RSV prevention to Canadian healthcare professionals on behalf of institution. No personal remuneration.		
AstraZeneca Australia	Other	Other - University of Western Australia
Category: Other Description: Scientific advisory board member Additional Information: Member of scientific advisory board for COVID-19 vaccines on behalf of institution (no remuneration)		
GlaxoSmithKline	Other	Other - University of Western Australia
Category: Other Description: Speaker engagement Additional Information: Speaking engagement on behalf of employer (UWA) for 2 lectures on meningococcal vaccines		
GlaxoSmithKline	Other	Self
Category: Other Description: Scientific Advisory Board member Additional Information: Member of vaccine advisory boards on behalf of employer, the University of WA		
GlaxoSmithKline	Other	Other - University of Western Australia
Category: Other Description: Speaking engagement Additional Information: Speaking engagements on behalf of employer for 5 lectures in meningococcal vaccines, Herpes zoster vaccines between June 2021 to October 2022		
Janssen Global Services, LLC	Other	Other - University of Western Australia
Category: Other Description: Member of Scientific advisory board Additional Information: Member of scientific advisory board on behalf of institution for novel RSV treatment in children		
Merck	Grant / Contract	Other - University of Western Australia

Entity	Type	Interest Held By
Recipient Name: University of Western Australia Grant / Contract Description: Investigator-Initiated research Proposal (MISP 60312) on RSV Epidemiology in children Additional Information: Investigator-Initiated research Proposal MISP 60312. "Characterising the epidemiology of RSV in Australian children through record linkage: clinical burden, outcomes and risk factors" 2021-2023 Funding to UWA Epidemiological study of RSV disease in children. CIB		
Merck	Grant / Contract	Other - University of Western Australia
Recipient Name: University of Western Australia Grant / Contract Description: Investigator-initiated study of the microbiology and aetiology of otitis media in Australia Additional Information: Investigator Initiated Grant MISP6056 " A cross-sectional observational study on the aetiology of recurrent acute otitis media in Western Australia in the PCV13-era: the WALLACE study (Western Australian Aetiology of Acute and Chronic Ear Disease). 2021-2023 to UWA Microbiology and epidemiology of otitis media in WA children		
Merck	Other	Other - University of Western Australia
Category: Other Description: Scientific Advisory Board Member Additional Information: Memnber of pneumococcal and RSV vaccines advisory boards (ongoing). Work on behalf of employer , the University of Western Australia. No personal remuneration.		
Merck	Other	Other - University of Western Australia
Category: Other Description: Speaker engagement Additional Information: Invited virtual speaker on RSV prevention at RSV monoclonal antibody study investigator meeting on behalf of employed. No personal remuneration.		
Pfizer	Other	Other - University of Western Australia
Category: Other Description: Member of Vaccine Scientific Advisory Board Additional Information: Member of vaccine advisory board for meningococcal and RSV vaccines on behalf of employer University of Western Australia		
SANOFI PASTEUR BIOLOGICS LLC	Other	Other - University of Western Australia
Category: Other Description: Scientif Advisory Board Additional Information: Member of scientific advisory boards (Regional and Australia) for RSV disease and prevention strategies on behalf of UWA. No personal remuneration		

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes.

- a. Please describe those relationships.

Board member of Resvinet Foundation- an international non-profit organization committed to reducing the global burden of RSV infection.

2. What is the manuscript title?

Bivalent RSVpreF Vaccine in Pregnancy to Prevent RSV Illness in Infants

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



katherine schneider

Discloser Identifier: 1100412

Disclosure Purpose: 22-16480

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
Title: Associate Director Additional Information:		Position Description: run a lab that develops diagnostic assays for infectious organisms
Pfizer	Stock	Self
Additional Information:		
Pfizer	Stock Option	Self
Additional Information:		

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Bivalent RSVpreF Vaccine in Pregnancy to Prevent RSV Illness in Infants

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Emma Shittu

Discloser Identifier: 1108088

Disclosure Purpose: 22-16480

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer	Stock	Self
Additional Information:		
Pfizer	Stock Option	Self
Additional Information:		
Pfizer UK	Employment	Self
Title: Director Additional Information: Position Description: Clinical Scientist		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Bivalent RSVpreF Vaccine in Pregnancy to Prevent RSV Illness in Infants

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 969319

Disclosure Purpose: 22-16480

Summary of Interests		
Company or Organization		
Entity	Type	Interest Held By
AstraZeneca	Grant / Contract	Other - To Childrens Hospital Colorado and Samshoma Medical Research Inc.
Recipient Name: Eric Simoes Grant / Contract Description: MEDLEY, MELODY Additional Information:Recipient Type: Institution Grant / Contract Purpose: Research		
GlaxoSmithKline	Data And Safety Monitoring	Other - Samshoma Medical Research Inc
Category: Data And Safety Monitoring Description: Maternal RSV Vaccine trials Additional Information:		
Merck	Grant / Contract	Other - To University of Colorado and Children's Hospital Colorado
Recipient Name: Eric Simoes Grant / Contract Description: MK1654-002, MK1654-004 Additional Information:Recipient Type: Institution Grant / Contract Purpose: Research		
Pfizer Inc.	Grant / Contract	Other - Children's Hospital Colorado and University of Colorado School of Medicine
Recipient Name: Eric Simoes Grant / Contract Description: Grants to conduct trials C4591007, C4591015, C3571002, C3671003, and C3671008, Additional Information:Recipient Type: Institution Grant / Contract Purpose: Research		
Regeneron Pharmaceuticals, Inc.	Grant / Contract	Other - University of Colorado School of Medicine and Samshoma Medical Research Inc
Recipient Name: Eric Simoes Grant / Contract Description: R10933-10987-COV-2069 and 0000-COV-CES-2053 Additional Information:Recipient Type: Institution Grant / Contract Purpose: Research		
SANOFI PASTEUR INC.	Consultant	Other - Samshoma Medical Research Inc
Category: Consultant Description: Ad Board Additional Information:		

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Bivalent RSVpreF Vaccine in Pregnancy to Prevent RSV Illness in Infants

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Discloser Identifier: 1108092

Disclosure Purpose: 22-16480

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer Inc.	Employment	Self
Title: Director- Vaccine Clinical Research and Development Additional Information:		Position Description:
Pfizer Inc.	Stock	Self
Additional Information:		
Pfizer Inc.	Stock Option	Self
Additional Information:		

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Bivalent RSVpreF Vaccine in Pregnancy to Prevent RSV Illness in Infants

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Nina Staerke

Discloser Identifier: 737718

Disclosure Purpose: 22-16480

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Bavarian Nordic A/S	Other	Self
<i>Category:</i> Other <i>Description:</i> Investigator in clinical study <i>Additional Information:</i>		
Pfizer Inc.	Other	Self
<i>Category:</i> Other <i>Description:</i> Investigator in clinical study <i>Additional Information:</i>		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Bivalent RSVpreF Vaccine in Pregnancy to Prevent RSV Illness in Infants

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Renato Stein

Discloser Identifier: 1108114

Disclosure Purpose: 22-16480

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AstraZeneca	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Consultant in different board meetings related to RSV <i>Additional Information:</i>		
Janssen Pharmaceuticals	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Consultant in different board meetings related to RSV <i>Additional Information:</i>		
Pfizer	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Consultant in different board meetings related to RSV <i>Additional Information:</i>		
Sanofi	Consultant	Self
<i>Category:</i> Consultant <i>Description:</i> Consultant in different board meetings related to RSV <i>Additional Information:</i>		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Bivalent RSVpreF Vaccine in Pregnancy to Prevent RSV Illness in Infants

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Kena Swanson

Discloser Identifier: 970664

Disclosure Purpose: 22-16480

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Vice President, Viral Vaccines <i>Additional Information:</i>		
<i>Position Description:</i> vaccine research and development		
Pfizer	Stock	Self
<i>Additional Information:</i>		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Bivalent RSVpreF Vaccine in Pregnancy to Prevent RSV Illness in Infants

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Bruce Tapiero

Discloser Identifier: 1108113

Disclosure Purpose: 22-16480

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Research Grants Council, University Grants Committee	Other	Self
<i>Category:</i> Other <i>Description:</i> Local sub investigator <i>Additional Information:</i> research grant attributed to the CHU Sainte Justine Research Center		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Bivalent RSVpreF Vaccine in Pregnancy to Prevent RSV Illness in Infants

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Marlies van Houten

Discloser Identifier: 1108106

Disclosure Purpose: 22-16480

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

"Bivalent RSVpreF Vaccine in Pregnancy to Prevent RSV Illness in Infants"

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Discloser Identifier: 1108110

Disclosure Purpose: 22-16480

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Bivalent RSVpreF Vaccine in Pregnancy to Prevent RSV Illness in Infants

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Philip Zachariah

Discloser Identifier: 1108093

Disclosure Purpose: 22-16480

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer Inc.	Employment	Self
Title: Associate Director Additional Information: Position Description: Medical Monitor for Vaccine Trials		
Pfizer Inc.	Stock	Self
Additional Information:		
Pfizer Inc.	Stock Option	Self
Additional Information:		

Additional Questions

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

No.

2. What is the manuscript title?

Bivalent RSVpreF Vaccine in Pregnancy to Prevent RSV Illness in Infants

3. Are you the corresponding author?

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Heather Zar

Discloser Identifier: 496190

Disclosure Purpose: 22-16480

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AstraZeneca	Grant / Contract	Other - institution
<i>Recipient Name:</i> University of Cape Town Lung Institute <i>Grant / Contract Description:</i> funding for studies of monoclonal antibody for RSV prevention in infants <i>Additional Information:</i> <i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
Merck	Grant / Contract	Other - institution
<i>Recipient Name:</i> University of Cape Town Lung Institute <i>Grant / Contract Description:</i> funding for studies of monoclonal antibody for prevention of RSV in infants <i>Additional Information:</i> <i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		
Pfizer Inc.	Grant / Contract	Other - institution
<i>Recipient Name:</i> University of Cape Town Lung Institute <i>Grant / Contract Description:</i> Funding for study of RSV vaccination in pregnant women <i>Additional Information:</i> <i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research		

Additional Questions

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Bivalent RSVpreF Vaccine in Pregnancy to Prevent RSV Illness in Infants

3. **Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Convey